Regorafenib is an oral multikinase inhibitor targeting VEGFR1–3, c-KIT, RAF, and FGFR, which inhibits tumor angiogenesis and significantly delays tumor growth, and has been approved for treating metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma (45, 46). Here, FLT1 is linked to gastrointestinal stromal tumor.